Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05272423 · ClinicalTrials.gov registry record
Studying Pathways of Resistance in KRAS-driven Cancers
A clinical trial of Kras P.G12C, sponsored by Addario Lung Cancer Medical Institute.
- Active
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT05272423: Active study of Kras P.G12C, sponsored by Addario Lung Cancer Medical Institute.
NCT05272423 is a study of Kras P.G12C that is active but no longer recruiting, run by Addario Lung Cancer Medical Institute. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05272423, a study of Kras P.G12C, is active but no longer recruiting, sponsored by Addario Lung Cancer Medical Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
Up to 250 patients from anywhere in the United States can remotely consent and participate to have plasma drawn locally and submitted to Foundation Medicine, Inc. (FMI), for the FoundationOne® Liquid Biopsy Assay. Patients who have had resistance mechanisms determined through other assays can also consent to share these data. The Investigator(s) will compare mechanisms of acquired resistance across drugs (e.g. sotorasib vs adagrasib) and between tumor types (e.g. NSCLC vs CRC) to determine if different resistance mutations arise in these settings.
Primary Outcome
The Investigator(s) will summarize mechanisms of acquired resistance with descriptive statistics (percentage and confidence interval), and compare across drugs (e.g., sotorasib vs adagrasib) and between tumor types (e.g., NSCLC vs CRC) to determine if different resistance mutations arise in these settings, using Fisher's exact test.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST FoundationOne® Liquid CDx
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2022-09-08 |
| Est. Completion | 2026-03 |
What the registry record for NCT05272423 still lists
NCT05272423 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Kras P.G12C appearing as the primary indexed condition, and to 1 intervention - of which FoundationOne® Liquid CDx is the first listed.
NCT05272423 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05272423 about?
NCT05272423 is a clinical study titled "Studying Pathways of Resistance in KRAS-driven Cancers". Up to 250 patients from anywhere in the United States can remotely consent and participate to have plasma drawn locally and submitted to Foundation Medicine, Inc. (FMI), for the FoundationOne® Liquid Biopsy Assay. Patients who have had resistance mechanisms determined through other assays can also c...
What is the current status of trial NCT05272423?
This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2022-09-08. Estimated completion is 2026-03.
What conditions does trial NCT05272423 study?
This clinical trial studies the following conditions: Kras P.G12C.
What interventions are being tested in trial NCT05272423?
The interventions under investigation include: FoundationOne® Liquid CDx (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05272423?
This trial is sponsored by Addario Lung Cancer Medical Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05272423 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kras P.G12C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI